



ASX Release
26 March 2019

Rights Issue Prospectus Shortfall

Pursuant to the Non-renounceable Rights Issue Prospectus dated 28 February 2019 and lodged with ASIC and ASX on same day, the rights offer closed on 21 March 2019.

A total of 182,044,573 rights to shares were offered under the Rights Issue and as at the closing date, 94,736,774 rights to shares were accepted.

The shortfall of 87,307,799 rights to shares are to be placed by the underwriter to the offer, Patersons Securities Limited.

For further information please contact:

Alison Coutts
Executive Chairman
Memphasys Limited
+61 2 8415 7300
alison.coutts@memphasys.com

David Tasker
Managing Director
Chapter One Advisors
+0433 112 936
dtasker@chapteroneadvisors.com.au

About Memphasys:

Memphasys Limited (ASX: MEM) specialises in biological separations for high value commercial applications. The Company's patented membrane processes in combination with electrophoresis, the application of an electrical potential difference across a fluid, enable the separation of high value substances or contaminants from the fluid in which they are contained.

The main application of the technology is the separation of the most viable sperm cells for artificial reproduction, most particularly for human IVF.